Prescription Drug Recall: Atomoxetine Capsules Due to Impurity
Glenmark Pharmaceuticals is recalling Atomoxetine 25mg capsules nationwide due to manufacturing deviations resulting in N-Nitroso Atomoxetine impurity above FDA limits. Consumers should contact their healthcare provider or pharmacist.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall involving a risk-of-harm product containing N-nitroso impurity, a known genotoxic substance above regulatory limits. No illnesses or injuries are reported in the source text, consistent with a precautionary manufacturing-compliance recall.
Plain-English summary
Glenmark Pharmaceuticals Inc., USA is recalling Atomoxetine Capsules, USP, 25 mg due to Current Good Manufacturing Practice (CGMP) deviations. The recalled product was manufactured by Glenmark Pharmaceuticals Ltd. in Goa, India and distributed nationwide within the United States under the brand name Atomoxetine with NDC 16714-757-01.
The recall was initiated because testing detected N-Nitroso Atomoxetine impurity levels that exceed the FDA recommended limit. This impurity resulted from manufacturing process deviations. A total of 133,824 bottles have been distributed.
The affected lot numbers are: 19232506, 19232397, 19232415 (Exp. 5/2025); 19233791 (Exp. 8/2025); 19234248 (Exp. 9/2025); 19240909 (Exp. 2/2026); 19242598 (Exp. 6/2026); 19243163, 19243122 (Exp. 7/2026); and 19243884 (Exp. 9/2026).
Consumers with affected bottles should not take the medication and should contact their healthcare provider or pharmacist for guidance. Healthcare providers and pharmacies should stop dispensing the affected lots immediately. This is a Prescription (Rx) only medication.
The recalled product
- Product
- ATOMOXETINE (ATOMOXETINE)
- Brand
- ATOMOXETINE
- Manufacturer
- Glenmark Pharmaceuticals Inc., USA
- Category
- Drug
- Affected units
- 133,824
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (17)
- Lot Numbers: 19232506
- 19232397
- 19232415
- Exp.: 5/2025
- 19233791
- Exp.: 8/2025
- 19234248
- Exp.: 9/2025
- 19240909
- Exp.: 2/2026
- 19242598
- Exp.:6/2026
- 19243163
- 19243122
- Exp.: 7/2026
- 19243884
- Exp.: 9/2026.
UPCs (5)
- 0316714760018
- 0316714755014
- 0316714756011
- 0316714761015
- 0316714757018
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 14 recalled by Glenmark Pharmaceuticals Inc., USA under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 14 products in this recall →Related recalls
Same brand · ATOMOXETINE
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- HighAtomoxetine Capsules Recalled for Elevated Nitrosamine Impurity
FDA (Drugs) · 2025-02-26
- HighAtomoxetine Capsules Recalled for Manufacturing Impurity Above Limits
FDA (Drugs) · 2025-02-26
- HighAtomoxetine Capsules Nationwide Recall for N-Nitroso Impurity Above FDA Limits
FDA (Drugs) · 2025-02-26
- ModerateAtomoxetine Capsules Recalled for Chemical Impurity Above FDA Limits
FDA (Drugs) · 2025-02-26
Same manufacturer · Glenmark Pharmaceuticals Inc., USA
See all →- ModerateAzelaic Acid Gel 15% Recalled Over Grainy, Gritty, or Sandy Texture
FDA (Drugs) · 2026-08-05
- ModerateAlyacen 7/7/7 birth control tablets failed total impurities specification
FDA (Drugs) · 2026-06-24
- ModerateOndansetron tablets recalled because blister packs are not fully sealed
FDA (Drugs) · 2026-01-07
- CriticalFrozen chopped methi recalled after testing positive for Salmonella
FDA (Drugs) · 2025-12-17
- ModerateBisoprolol and hydrochlorothiazide tablets recalled over traces of another drug
FDA (Drugs) · 2025-12-10
Same hazard · nitrosamine impurity
See all →- HighEnovachem duloxetine capsules exceed the nitrosamine acceptable intake limit
FDA (Drugs) · 2026-06-10
- HighCipla cinacalcet 60 mg tablets exceed the nitrosamine daily intake limit
FDA (Drugs) · 2026-04-22
- HighCipla cinacalcet 30 mg tablets exceed the nitrosamine daily intake limit
FDA (Drugs) · 2026-04-22
- HighCipla cinacalcet 90 mg tablets exceed the nitrosamine daily intake limit
FDA (Drugs) · 2026-04-22
- HighPrazosin hydrochloride 100-count bottles recalled over nitrosamine impurity
FDA (Drugs) · 2026-04-08